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Objectives: To examine the interaction between ST segment depression on the baseline ECG and
subsequent in-hospital revascularisation on six month mortality among patients with non-ST elevation
acute coronary syndromes. To examine whether ST segment depression influenced clinical decision
making and whether there was international variation in the use of cardiac procedures across ST segment
depression categories.
Methods: 11 453 patients enrolled in GUSTO-IIB (global use of strategies to open occluded coronary
arteries), PARAGON (platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a
global organisation network) -A, and PARAGON-B were studied. Patients were categorised as having no
ST segment depression, 1 mm ST segment depression in two contiguous leads, and ST segment depression
> 2 mm in two contiguous leads. International practice across four geographic regions was examined:
USA, Canada, Europe, and Australia/New Zealand.
Results: Revascularisation appeared to have no impact on survival among patients with no ST segment
depression; however, revascularisation was associated with a significant survival benefit among patients
with ST segment depression > 1 mm. There was an inverse relation between the extent of ST segment
depression and the use of angiography as well as angioplasty (p , 0.01). However, patients with ST
segment depression > 2 mm were more likely to undergo bypass surgery. The only significant trend of
increasing use of revascularisation procedures with increasing ST segment depression was observed in the
USA.
Conclusions: International practice patterns in procedure use appear to be insensitive to the extent of ST
segment depression. Major opportunities for more efficient delivery of care exist in all regions.
I
n the ongoing debate regarding conservative versus
aggressive treatment of patients presenting with non-ST
elevation acute coronary syndromes (ACS), there is
growing consensus that high risk patients are likely to
benefit most from early revascularisation.1 We, and other
investigators, have previously shown that identification of
high risk patients can be facilitated through the use of a
readily available diagnostic tool: the baseline ECG.2–6 While
there is little doubt that greater ST segment depression on the
baseline ECG is associated with worse outcomes among
patients with ACS, data from the FRISC-II (Fragmin and fast
revascularization during instability in coronary artery dis-
ease) and TACTICS-TIMI-18 (treat angina with Aggrastat
and determine cost of therapy with invasive or conservative
strategy-thrombolysis in myocardial infarction) and a reana-
lysis of the TIMI-IIIB study suggest that ST segment
depression may offer additional insights into identifying
optimal candidates for revascularisation.7–9
In data from three major international non-ST elevation
ACS trials, which were conducted before publication of
evidence that revascularisation may be most beneficial
among patients with ST segment depression > 1 mm, we
examined the interaction between the extent of ST segment
depression on the baseline ECG and in-hospital revascular-
isation (percutaneous coronary intervention (PCI) or cor-
onary artery bypass graft surgery (CABG)) on six month
mortality outcomes. We also examined the degree of
international variation in the use of diagnostic and treatment
procedures for these patients during the index hospitalisa-
tion. The results of our study would serve as important
benchmarks against which the impact of subsequent studies
and guidelines on clinical practice can be evaluated.
METHODS
Study population
The GUSTO-IIB (global use of strategies to open occluded
coronary arteries)10 and the PARAGON (platelet IIb/IIIa
antagonism for the reduction of acute coronary syndrome
events in a global organisation network) -A and PARAGON-B
studies11 12 collectively enrolled 15 518 patients with unstable
angina and non-ST myocardial infarction over a five year
period (1994 to 1998). Inclusion criteria for the three trials
were similar: patients presenting with chest discomfort
within 12 hours of symptom onset with transient or
persistent ST segment depression > 0.5 mm or T wave
inversion, or transient ST segment elevation > 0.5 mm (30
minutes), were eligible for enrolment.
The current study population consisted of 8011 patients
enrolled between 1994 and 1995 in GUSTO-IIB, 2282 patients
enrolled between 1995 and 1996 in PARAGON-A, and 1160
Abbreviations: ACS, acute coronary syndromes; FRISC-II, Fragmin and
fast revascularization during instability in coronary artery disease;
GUSTO-IIB, global use of strategies to open occluded coronary arteries;
PARAGON, platelet IIb/IIIa antagonism for the reduction of acute
coronary syndrome events in a global organisation network; PCI,
percutaneous coronary intervention; TACTICS-TIMI-18, treat angina with
Aggrastat and determine cost of therapy with invasive or conservative
strategy-thrombolysis in myocardial infarction
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patients enrolled during 1998 in the PARAGON-B troponin
substudy.13 The 1160 patients enrolled in the PARAGON-B
troponin substudy, whose ECGs were evaluated by a central
core laboratory, constituted a prospectively selected random
sample of the overall 5225 patients enrolled in the
PARAGON-B trial. Of the total 11 453 patients, baseline
ECG data were available for 10 369 (91%). Patients
(n = 1521) with factors potentially confounding ECG
interpretation—that is, left bundle branch block, right bundle
branch block, interventricular conduction delay, left ventri-
cular hypertrophy, ventricular rhythm, or ventricular
pacing—were excluded from this study.
ECG parameters
ECGs were evaluated at central core laboratories at Duke
University, the Canadian Heart Research Centre, and the
University of Alberta. Baseline ECGs were recorded in 12 lead
format at a paper speed of 25 mm/s. ST segment depression
was judged to be present if the J point was depressed by
1 mm or more and was followed by a horizontal or down-
ward sloping ST segment for at least 0.08 seconds in all leads
except aVR. ST segment depression was measured and
rounded off to the nearest 1 mm. For our analysis, patients
were categorised into three mutually exclusive groups: no ST
depression, 1 mm ST depression, or > 2 mm ST depression.
For limb leads, a minimum of two leads in orderly
arrangement (aVL and I, II and aVF, or aVF and III) each
having 1 or 2 mm ST depression was required for qualifying
as 1 or 2 mm ST depression, respectively. For precordial leads,
a minimum of two contiguous leads (V1 and V2, V2 and V3,
V3 and 4V, and so on) each having 1 or 2 mm ST depression
was required for qualifying as 1 or 2 mm ST depression,
respectively.
International practice patterns
To examine variations in international practice patterns,
patients were grouped according to country of enrolment.
Four regions were identified: USA (2143); Canada (1023);
Europe (4438); and Australia/New Zealand (1013). Owing to
the diverse geographic distribution of the remaining 231
patients (Argentina (159), Israel (76), South Africa (46), and
Brazil (4)), they were excluded from the analysis. The
appendix provides the specific countries constituting each
region.
In GUSTO-IIB coronary angiography, PCI and CABG were
discouraged for the duration of the study drug infusion
(mean duration of treatment was 75 hours) unless there was
evidence of recurrent ischaemia. Similarly, in PARAGON-A
cardiac procedures were discouraged for the first 48 hours
unless clinically necessitated by haemodynamic instability or
recurrent ischaemia. In PARAGON-B, the protocol did not
specify guidelines regarding the use of cardiac procedures
and all procedures were performed according to local
standards of practice.
Revascularisation procedures were recorded for all patients
if they were done within the index hospitalisation. Thirty day
rates of revascularisation reported by patients were also
collected in all three trials. Index hospital rates of use of
diagnostic procedures (stress tests and angiography) and
revascularisation procedures (PCI and CABG) across ST
segment depression category, overall and within each region,
were compared. The rates of revascularisation procedure use
for patients who underwent angiography were also exam-
ined.
Statistical analyses
x2 tests (for categorical variables) and the non-parametric
Kruskal-Wallis tests (for continuous variables) were used to
compare characteristics across groups of patients.
Angiography and revascularisation procedure rates across
ST segment depression categories were compared by x2 tests
for trends. Kaplan-Meier analysis was used to study the
association between revascularisation and six month mor-
tality across ST segment depression categories. To reduce
selection bias associated with treating patients who did not
survive long enough to undergo revascularisation as non-
revascularised patients, we performed a landmark analysis.14
In this analysis, which effectively removes the bias as a result
of early hazard, only those patients who had survived to six
days (that is, who had the opportunity to undergo
Table 1 Baseline characteristics by extent of ST segment depression
Characteristic
ST segment depression
p ValueNone (n = 4160) 1 mm (n = 3098) >2 mm (n = 1590)
Age (years) 63 (53, 71) 66 (57, 73) 68 (60, 75) ,0.01
Women 33.5% 37.3% 31.6% ,0.01
Heart rate (beats/min) 71 (61, 81) 75 (65, 85) 80 (70, 94) ,0.01
Systolic BP (mm Hg) 135 (120, 150) 140 (122, 155) 140 (120, 155) ,0.01
Diastolic BP (mm Hg) 80 (70, 89) 80 (70, 90) 80 (70, 90) ,0.01
Hypertension 45.6% 48.9% 50.3% ,0.01
Diabetes 17.3% 19.2% 19.8% 0.03
Family history of CAD 42.1% 38.8% 36.7% ,0.01
Hypercholesterolaemia 41.7% 43.0% 41.9% 0.51
Congestive heart failure 5.0% 7.4% 8.4% ,0.01
Previous angina 74.8% 73.7% 74.0% 0.55
Previous MI 31.1% 29.3% 34.8% ,0.01
Previous PTCA 12.4% 9.5% 6.8% ,0.01
Previous CABG 11.2% 11.7% 8.4% ,0.01
COPD 2.8% 2.6% 3.6% 0.12
PVD 6.2% 8.4% 11.3% ,0.01
Enrolment MI 35.2% 43.0% 58.9% ,0.01
Regions ,0.01
USA 58.8% 26.6% 14.6%
Canada 55.5% 28.0% 16.5%
Europe 40.6% 38.7% 20.7%
Australia/NZ 42.6% 42.1% 15.3%
Continuous variables presented as median (25th, 75th centile).
BP, blood pressure; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; NZ, New Zealand; PTCA, percutaneous transluminal
coronary angioplasty; PVD, peripheral vascular disease.
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revascularisation) were included. The six day cut off was
chosen because the median time to revascularisation in the
cohort was six days (interquartile range 3–10 days). Survival
curves were compared by the log rank test statistic. We used
Cox regression analysis to examine the association between
baseline variables and six month mortality. Given that
revascularisation is not a baseline variable, it was included
as a time dependent covariate, and the interaction between
revascularisation status and the presence of ST segment
depression > 1 mm was examined.15
RESULTS
Patient population
Of the total 11 453 study patients, ECG data were available
for 10 369 (91%). Patients with missing ECG data were less
likely to have a myocardial infarction on presentation and
had lower frequency of prior revascularisation procedures.
There were no other significant differences in baseline
characteristics between the two groups. After exclusion of
1521 patients with ECG confounders, the final study sample
comprised 8848 patients. The distribution of these patients
across ST segment depression categories was as follows: 4160
(47%) had no ST segment depression; 3098 (35%) had ST
segment depression of 1 mm; and 1590 (18%) had ST
segment depression > 2 mm.
Table 1 provides baseline and clinical characteristics of
study patients according to ST segment depression status.
Patients with ST segment depression > 2 mm were older,
more likely to be men, and less likely to have undergone a
previous PCI or CABG. The frequency of risk factors including
hypertension and diabetes was higher in these patients and
they more often had congestive heart failure, previous
myocardial infarction, and peripheral vascular disease. In
addition, the likelihood of presenting with myocardial
infarction as the index event increased with the extent of
ST segment depression (35% among patients with no ST
segment depression, 43% among patients with ST segment
depression of 1 mm, and 59% among patients with ST
segment depression > 2 mm; p , 0.01). In keeping with the





























































Figure 1 Use of angiography and revascularisation procedures across ST segment depression (STQ) categories (left) overall and (right) among
patients who underwent angiography. CABG, coronary artery bypass graft surgery; PCI, percutaneous coronary intervention. *x2 test for trend
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Figure 2 Unadjusted six month survival by ST segment category and revascularisation status. To reduce selection bias associated with treating patients
who did not survive long enough to undergo revascularisation as non-revascularised patients, this analysis was restricted to patients who had survived
to six days after admission.
Table 2 Variables associated with a higher mortality
hazard at six months based on Cox regression analysis
Variable HR 95% CI x2
Age 1.06 1.05 to 1.07 128.6
ST segment depression >1 mm 1.96 1.59 to 2.41 39.1
Diabetes 1.74 1.43 to 2.12 31.0
MI on enrolment 1.57 1.31 to 1.89 23.4
Congestive heart failure 1.84 1.45 to 2.33 24.8
COPD 1.96 1.40 to 2.76 15.3
PVD 1.59 1.25 to 2.03 14.0
Previous MI 1.43 1.18 to 1.74 13.7
Previous angina 1.52 1.17 to 1.97 9.6
Hypercholesterolaemia 0.85 0.70 to 1.02 2.9
CI, confidence interval; HR, hazard ratio.
878 Kaul, Newby, Fu, et al
www.heartjnl.com
higher among patients with ST segment depression > 2 mm
(2.9% among patients with no ST segment depression, 5.3%
among patients with 1 mm ST segment depression, and
11.7% among patients with ST segment depression > 2 mm;
p , 0.01).
Figure 1 shows the rates of angiography, PCI, and CABG
use across ST segment depression categories. There was an
inverse relation between extent of ST segment depression
and the use of angiography and PCI (p , 0.01); however,
patients with ST segment depression > 2 mm were more
likely to undergo CABG (p , 0.01). Revascularisation pat-
terns across ST segment depression categories were similar
when the analysis was restricted to patients who had
undergone angiography (fig 1, right panel). Among patients
with no ST segment depression, those who had a previous
PCI or recurrent ischaemia were more likely to undergo
coronary angiography, whereas women and older patients
were less likely to do so. Similarly, among patients with ST
segment depression > 2 mm, patients who were younger,
were men, had hypercholesterolaemia, a family history of
coronary artery disease, prior PCI, and no peripheral vascular
disease, and did not have a myocardial infarction on
enrolment, were more likely to undergo revascularisation.
To ensure that our results were not influenced by the time
window of the study—that is, the index hospitalisation—we
examined 30 day rates of PCI and CABG by ST segment
depression category. The patterns were similar to those
observed during the index hospitalisation with cumulative 30
day PCI rates of 23.7%, 21%, and 17.7% and cumulative
CABG rates of 13.4%, 15.8%, and 22.1% among patients with
no ST segment depression, ST segment depression of 1 mm,
and ST segment depression > 2 mm, respectively.
Figure 2 shows the relation of revascularisation and six
month mortality (among six day survivors) across the three
ST segment depression categories. Revascularisation
appeared to have no relation with survival among patients
with no ST segment depression; however, it was associated
with significantly better survival among patients with 1 mm
ST segment depression (2.6% among revascularised patients
and 4.7% among non-revascularised patients, p , 0.01) and
among patients with ST segment depression > 2 mm (4.8%
among revascularised patients and 9.3% among non-revas-
cularised patients, p , 0.01). In a multivariable Cox regres-
sion model, patient’s age and ST segment depression
> 1 mm were the strongest predictors of six month mortality
accounting for 55% of the model’s predictive power (table 2).
On inclusion of revascularisation status as a time dependent
covariate, the main effect of revascularisation was non-
significant. However, the interaction between revascularisa-
tion and the presence of ST segment depression > 1 mm was
significant (hazard ratio 0.62, 95% CI 0.38 to 1.0) suggesting
that revascularisation was beneficial for patients with ST
segment depression of> 1 mm, after adjustment for baseline
variables.
International practice patterns
Of the 8848 patients enrolled in the study, 2143 (24%) were
enrolled in the USA, 1023 (12%) in Canada, 4438 (50%) in
Europe, 1013 (11%) in Australia/New Zealand, and 231 (3%)
in other countries that were excluded from the analysis.
Table 1 shows the distribution of ST segment depression
across region of enrolment. Compared with the other regions,
European countries enrolled a significantly higher number of
patients with ST segment depression > 2 mm (15% in the
USA, 17% in Canada, 21% in Europe, and 15% in Australia/
New Zealand, p , 0.01).
The use of stress tests was higher in Canada and Europe,
whereas the rates of angiography use were significantly
higher in the USA than in the other regions (fig 3). There
were no significant differences in the use of angiography
across ST segment depression categories. Figure 4 presents
region specific procedure rates across ST segment depression
categories. In general, use of PCI decreased with extent of ST
segment depression category (fig 4, panel A). In contrast,
rates of CABG increased with extent of ST segment
depression (fig 4, panel B) in both the USA and Europe.
The highest correlation between ST segment depression and
CABG use was in the USA with rates of 17% in patients with
no ST segment depression, 24% in patients with 1 mm ST
segment depression, and 33% in patients with ST segment
depression > 2 mm (p value for trend , 0.01). When we
examined the combined revascularisation rates (for PCI or
CABG), the only significant trends in procedure use across ST
segment depression categories was observed in the USA (fig 4,
panel C). The patterns across ST segment depression
categories remained consistent when revascularisation rates
were calculated for only those patients who had undergone
coronary angiography.
DISCUSSION
The key finding of our study was the paradoxical absence of a
relation between the extent of baseline ST segment depres-
sion and the use of an invasive diagnostic and management
strategy for patients with ACS. In fact, an invasive strategy
was selected least often for those at highest risk for adverse



































































Figure 3 Use of diagnostic tests by ST segment depression category and geographic region: (A) stress tests; (B) angiography. *x2 test for trend
significant at p,0.05.
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Firstly, because our findings, like those of others,9 16 17
suggest a greater benefit from revascularisation for patients
with ST segment depression of > 1 mm, failure to apply the
results of this simple risk stratification tool may result in
suboptimal clinical outcomes in regions where angiography
rates are low regardless of ECG presentation. Conversely, in
regions where angiography rates are high regardless of ECG
presentation, resource use and costs may not be optimised.
Prior studies
Our findings of the association between early revascularisa-
tion and mortality across ST segment depression categories,
based on the largest database of patients with ACS with core
laboratory ECG evaluations, are consistent with the results of
subanalyses of the FRISC-II study.16 17 In the FRISC-II ECG
substudy, Diderholm et al16 found that among patients with
ST segment depression (defined as . 0.5 mm) an early
invasive strategy was associated with a significant reduction
in one year mortality (from 5.8% to 3.3%, p = 0.004).
Holmvang et al17 extended this analysis to include cumulative
ST segment depression and the number of leads with ST
segment depression . 0.5 mm. Similar to our findings, they
found that invasive treatment was associated with lower
mortality among all patients except those with minor ST
segment deviations.
International practice patterns
Assessing performance and providing feedback have been
described as integral components of improving quality of
health care delivery.18 Our examination of international
practice patterns between 1995 and 1998 is an excellent
benchmark against which to measure the impact of recent
American College of Cardiology/American Heart Association
guidelines and European Society of Cardiology guidelines,
which offer a class 1A recommendation for the use of early
invasive treatment for patients with ACS presenting with
new or presumably new ST segment deviations.19 20 Our study
has several findings that are relevant to clinical practitioners
as well as policymakers. Firstly, a higher percentage of
patients with ST segment depression was enrolled in Europe
(59%) than in North America (41% in the USA and 44% in
Canada; table 1). This may contribute to the increased
mortality documented in European countries in previous
studies.21 22 Secondly, as documented previously, the USA had
the highest rates of angiography among the regions (fig 3).23
A consequence of such an aggressive management strategy
was the identification of the highest percentage of candidates
for CABG not only among patients with ST segment
depression > 2 mm (33% compared with 14% in Canada,
15% in Europe, and 11% in Australia/New Zealand) but also
among patients with no ST segment depression (17%
compared with 8% in Canada, 9% in Europe, and 8% in
Australia/New Zealand). This may, in part, explain the
observed benefit from an early invasive risk stratification
strategy compared with a conservative strategy in clinical
trials. Thirdly, and most important, major opportunities
remain to improve clinical decision making with respect to
the use of revascularisation in all regions but especially in
Canada and Europe. In these regions, there were no
significant differences in revascularisation rates across ST
segment depression categories, and only a third of the
patients most likely to benefit from revascularisation received
it. In the USA, although revascularisation rates appear more
sensitive to the extent of ST segment depression, of the 59%
of patients without ST segment depression for whom
revascularisation appears to offer no benefit, 81% under-
went angiography and 49% underwent PCI or CABG.
Channelling of these resources towards more high risk
patients should result in more cost effective and efficient
delivery of care.
Some limitations of our study should be noted. Owing to
the observational nature of the study design and the fact that
revascularisation was a post-randomisation event, the asso-
ciation between revascularisation and outcomes must be
considered hypothesis generating. Secondly, our study
examined practice patterns within the context of clinical
trials, which may not be entirely representative of overall
practice. However, to the extent that practice patterns among
clinicians participating in clinical trials are likely to be more
evidence based, even more opportunities to improve practice
probably exist at a population level. Thirdly, protocols for
GUSTO-IIB and PARAGON-A discouraged the use of early
revascularisation unless necessitated by the presence of




























































































Figure 4 Use of revascularisation procedures by ST segment
depression categories and geographic region: (A) PCI; (B) CABG;
(C) either PCI or CABG.
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unlikely to explain the large differences in practice patterns
across ST segment categories in the four regions. This is
substantiated by the similarity of patterns in PARAGON-B in
which revascularisation decisions were left entirely to the
practitioner’s discretion. Fourthly, our study did not capture
procedure rates beyond 30 days. To the extent that time to
revascularisation, especially for CABG, is longer in Europe,
our rates may underestimate the overall revascularisation
rates in this region. Lastly, several countries were grouped
together in the European region and the contributions of
patients to the three trials differed significantly for many of
the countries. The heterogeneity of countries within these
regions is not accounted for in these analyses.
Conclusions
We found in data from three large international ACS trials
with core laboratory ECG evaluations that revascularisation
had no apparent impact on outcomes among patients with no
ST segment depression but was associated with significantly
lower mortality rates among patients with > 1 mm ST
segment depression. International practice patterns with
respect to diagnostic and revascularisation procedures appear
to be insensitive to the extent of ST segment depression on
the baseline ECG. Major opportunities for more efficient
delivery of care exist in all regions.
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APPENDIX
List of countries (number of patients enrolled in all
three trials)
USA (2143); Canada (1023); Europe (4438): Belgium (665);
France (585); Germany (176); Italy (1003); Netherlands
(755); Spain (670); Sweden (188);United Kingdom (179);
Switzerland (68); Poland (451); Portugal (28); Iceland (67);
Finland (182); Denmark (54); Hungary (145); Australia/
New Zealand (1013): Australia (855); New Zealand (158);
Other (231): Argentina (159); Brazil (4); Israel (76); South
Africa (46).
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